Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

作者：Amy E. Colson, Anthony Mills, Moti Ramgopal, Christopher Bettacchi, Olayemi O Osiyemi, Federico Hinestrosa, Gordon Crofoot, Harold Katner, Hiroyuki Gatanaga, Margaret Johnson, Tracy L. Diamond, Erika Barninger, Karen Eves, Feng-Hsiu Su, Yayun Xu, Stephanie O. Klopfer, Luisa M. Stamm, Michelle C Fox, Rima Lahoulou · 发表于：The Lancet · 年份：2026 · DOI：10.1016/s0140-6736(25)01948-8 · 被引用次数：14 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、HIV/AIDS Research and Interventions